Entero Therapeutics, Inc. (NASDAQ:GRDX) Stock Short Interest Climbs 91.8%

Entero Therapeutics, Inc. (NASDAQ:GRDX – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 104,553 shares, a growth of 91.8% from the September 15th total of 54,523 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 74,913 shares, the days-to-cover ratio is presently 1.4 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 29th.

Get Entero Therapeutics alerts:

View Our Latest Research Report on Entero Therapeutics

Entero Therapeutics Stock Performance

GRDX traded down $0.30 during midday trading on Wednesday, hitting $4.25. The company had a trading volume of 62,258 shares, compared to its average volume of 115,623. Entero Therapeutics has a twelve month low of $1.87 and a twelve month high of $6.93. The company has a market capitalization of $30.30 million, a PE ratio of -2.24 and a beta of 1.69. The firm’s 50-day simple moving average is $3.58 and its 200-day simple moving average is $3.68.

Entero Therapeutics Company Profile

(Get Free Report)

Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health.

Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure.

Read More

• Five stocks we like better than Entero Therapeutics
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.